Evidence map›Paper›PMID 39600114›Full record

ArticleJournal of the American Geriatrics Society2025

Deprescribing considerations for central nervous system-active polypharmacy in patients with dementia.

Anna Hung, Matthew E Growdon

Abstract readEditorial
In one paragraph

Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna HungDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Matthew E GrowdonDivision of Geriatrics, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5997-4406

Funding

VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Keliimoeanu Smith · 2013 to 2026
$19.9M
U.S. Deprescribing Research NetworkR24AG064025 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI BOYD, CYNTHIA MELINDA, STEINMAN, MICHAEL A. · 2019 to 2023
$9.9M
Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
Optimizing medication use and support among people with dementia who live aloneK76AG088411 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Evan Growdon · 2024 to 2026
$804k
Medication risks and challenges among people with dementia who live aloneR03AG078804 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GROWDON, MATTHEW EVAN · 2022 to 2023
$323k
Helping Veterans Navigate Dual Pharmacy BenefitsIK2HX003359 · VA · DURHAM VA MEDICAL CENTER · PI Anna Hung · 2022 to 2026
–
HSRD VA CIN 13-410HSRD VA IK2 HX003359NIA NIH HHS K76 AG088411NIA NIH HHS K76AG088411NIA NIH HHS P30 AG044281NIA NIH HHS R03 AG078804NIA NIH HHS R03AG078804NIA NIH HHS R24 AG064025NIA NIH HHS R24AG064025NIA NIH HHS R33 AG057806NIA NIH HHS R33AG057806
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39600114
PMCPMC11828677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.